GlassScriptPhysician profile
Patrick S Dispoto
NPI 1659815710
$5,079.34
in general payments reported to CMS, 2019-2025
19 companies · $1,911 in 2025
The $1,911 reported for 2025 was more than what 95% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $521 · 2023: $962 · 2024: $1,686 · 2025: $1,911.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,558.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,558.11 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alkermes, INC. | $1,145.91 | 2022-2025 | Aristada, Lybalvi, Vivitrol |
| Neurocrine Biosciences, INC. | $709.89 | 2022-2025 | Ingrezza |
| Otsuka America Pharmaceutical, INC. | $701.48 | 2022-2025 | Rexulti, Abilify Maintena, Abilify Asimtufii |
| Abbvie INC. | $462.59 | 2022-2025 | |
| Teva Pharmaceuticals USA, INC. | $323.61 | 2022-2025 | Uzedy, Austedo Xr, Austedo Xr |
| Janssen Pharmaceuticals, INC | $321.40 | 2022-2025 | Invega Sustenna, Spravato, Invega Trinza |
| Vanda Pharmaceuticals INC. | $287.07 | 2024-2025 | Fanapt, Hetlioz |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $215.70 | 2023-2025 | Caplyta |
| E.R. Squibb & Sons, L.L.C. | $194.11 | 2024-2025 | Cobenfy |
| Lundbeck LLC | $150.45 | 2023-2025 | Rexulti, Abilify Asimtufii |
| Indivior INC. | $132.81 | 2023-2025 | Sublocade, Perseris |
| Almatica Pharma LLC | $122.20 | 2023-2025 | Loreev Xr, Sertraline Hcl |
| Ironshore Pharmaceuticals INC. | $85.99 | 2023-2024 | Jornay Pm |
| Supernus Pharmaceuticals, INC. | $77.25 | 2025 | Qelbree |
| Takeda Pharmaceuticals U.S.A., INC. | $43.80 | 2023-2024 | Trintellix |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Idorsia Pharmaceuticals US INC | $32.85 | 2023 | Quviviq |
| Sunovion Pharmaceuticals INC. | $31.06 | 2022 | |
| Luye Pharma (USA) LTD. | $25.24 | 2025 | Erzofri Extended-Release |
| Harmony Biosciences LLC | $15.93 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Patrick Dispoto listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.